in-vivo-pharmacology
(2)
Melior Discovery
Melior Discovery is an Exton, Pennsylvania preclinical contract research organization that specializes in in vivo pharmacology and drug repositioning. Its proprietary theraTRACE platform runs a candidate compound through a large, multiplexed panel of validated animal disease models simultaneously, systematically surfacing new therapeutic uses for existing or shelved drugs. Founded in 2005 by Andrew Reaume and Michael Saporito, the company both partners with major pharmaceutical firms and builds its own drug pipeline through spinouts, and was named CRO of the Year by Life Sciences Review in 2024.
Andrew Reaume
Andrew Reaume is the co-founder, President and CEO of Melior Discovery, an Exton, Pennsylvania preclinical contract research organization built around theraTRACE, a multiplexed in vivo phenotypic screening platform that runs a single drug candidate through a battery of animal disease models at once to uncover unexpected therapeutic uses. A geneticist by training with a Wharton MBA, he conceived the idea at Pfizer, left in 2005 to build it, and has since raised over $15 million in capital, closed more than $40 million in partnering deals, and pushed a repurposed compound, MLR-1023, into Phase 2 diabetes trials.